Your AI-Trained Oncology Knowledge Connection!
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease in myeloma.
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the molecular understanding of clear cell renal cell carcinoma (RCC).
You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of locally ablative therapy in patients with oligometastatic non–small cell lung cancer.
Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the potential of pembrolizumab in the treatment of patients with small cell lung cancer.
Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the safety and efficacy of the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).
Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses ways of extending the reach of CAR T-cell therapy in real-world practice.
Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).
Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.
Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.
Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the toxicity of androgen receptor inhibitors in castration-resistant prostate cancer.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).
Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program and associate professor, Department of Medicine, Division of Oncology, University of Washington, and medical oncologist, Seattle Cancer Care Alliance, discusses investigational immunotherapy approaches in localized bladder cancer.
David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses biochemical recurrence in patients with prostate cancer.
Rolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.
Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.
Umberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.
Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.
Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.
Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the FDA accelerated approval of erdafitinib (Balversa) in bladder cancer.
Eric Stephen Winer, MD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the FDA approval of ivosidenib in acute myeloid leukemia (AML).
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses promising therapies in newly diagnosed ovarian cancer.
Scott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.
Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.
Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses key updates in the treatment of patients with chronic lymphocytic leukemia.
Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses ongoing research with CAR T-cell therapy.
Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses sequencing strategies for patients with gastroenteropancreatic neuroendocrine tumors.
Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).
Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses emerging molecular markers in patients with metastatic colorectal cancer (mCRC).
David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses the role of surgery in stage III non–small cell lung cancer.
